Biomarkers for Systemic Therapy in Ovarian Cancer

ISSN: 1873-5576 (Online)
ISSN: 1568-0096 (Print)


Volume 14, 9 Issues, 2014


Download PDF Flyer




Current Cancer Drug Targets

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 67th of 202 in Oncology

Submit Abstracts Online Submit Manuscripts Online

Editor-in-Chief:
Ruiwen Zhang
Texas Tech University Health Sciences Center
1300 Coulter Drive
Amarillo, TX 79106
USA


View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 3.582
5 - Year: 3.859

Biomarkers for Systemic Therapy in Ovarian Cancer

Author(s): Zsofia Penzvalto, Pawel Surowiak and Balazs Gyorffy

Affiliation: Semmelweis University 1st Dept. of Pediatrics, Bókay u. 53-54., Budapest, H-1083, Hungary.

Abstract

Epithelial ovarian cancer (EOC) is the most deadly tumor of the female reproductive system. Despite improvements in understanding the biology of EOC, therapeutic strategies still depend on surgery and combination of taxane and platinum agents. Here, we provide a summary of clinically tested biomarkers potentially useful to predict drug response. Resistance against platinum derivatives can result from lower drug concentrations, alterations in the target molecule and changes in the cellular signal transduction pathways. Taxane resistance can develop due to decreased intracellular drug concentration, alterations in microtubuli structure and changes in the cellular response including ERBB2 (epidermal growth factor receptor 2). A few key genes have been suggested as biomarkers for hormonal therapy. Currently, the only targeted therapy agent approved for ovarian cancer is the VEGF (vascular endothelial growth factor) inhibitor bevacizumab. Response to bevacizumab is correlated with VEGF-A levels and hypertension. The primary problems in identifying reliable biomarkers for EOC are the usage of different clinical endpoints, multivariate analysis for a panel of clinical parameters and the lack of published comprehensive clinical information of patients enrolled in these studies. The future lies in adding targeted agents to the taxane/platinum gold standard and in a more detailed stratification of patients into sub-cohorts enabling a more effective therapy. In conclusion, a large-scale coordinated effort is needed for the robust validation of the numerous biomarker candidates available in EOC therapy.

Keywords: Biomarkers, ovarian cancer, platinum, resistance, systemic therapy, survival, taxane.

Purchase Online Order Reprints Order Eprints Rights and Permissions

  
  



Article Details

Volume: 14
Issue Number: 3
First Page: 259
Last Page: 273
Page Count: 15
DOI: 10.2174/1568009614666140310120107
Advertisement

Related Journals




Webmaster Contact: urooj@benthamscience.org Copyright © 2014 Bentham Science